A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c

UnknownOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

March 29, 2016

Primary Completion Date

October 10, 2017

Study Completion Date

October 28, 2019

Conditions
Melanoma
Interventions
BIOLOGICAL

OrienX010

Beijing biological technology co., LTD. Research and development of the source and force of recombinant human GM-CSF herpes simplex virus injection (OrienX010), is a genetically engineered type 1 herpes simplex virus (HSV - 1) as the carrier insert GM-CSF gene therapy drug.Its carrier is made of isolated from patients with oral Chinese wild single blister virus type I (CL1), after gene recombination technology successively removing ICP34.5, ICP47 and insert the deactivation ICP6 gene, and at the site of the original ICP34.5 insert guided by IE promoter of hCMV human GM-CSF gene.

Trial Locations (1)

100010

RECRUITING

Beijing cancer hospital, Beijing

Sponsors
All Listed Sponsors
lead

OrienGene Biotechnology Ltd.

INDUSTRY

NCT03048253 - A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c | Biotech Hunter | Biotech Hunter